* indication for full therapeutic-dose anticoagulation * acute venous thromboembolism (deep vein thrombosis or pulmonary embolism) within prior 3 months * acute cardiovascular event within prior 3 months * acute stroke (ischemic or hemorrhagic) within prior 3 months * active major bleeding * severe thrombocytopenia (\<25,000/mm3) * increased risk of bleeding, as assessed by the investigator * acute or chronic renal insufficiency with creatinine clearance \< 30 ml/min calculated by the modified cockcroft and gault formula * weight \< 40 kg * known allergies to ingredients contained in enoxaparin, allergy to heparin products or history of heparin induced thrombocytopenia

* indication for full therapeutic-dose anticoagulation * acute venous thromboembolism (deep vein thrombosis or pulmonary embolism) within prior 3 months * acute cardiovascular event within prior 3 months * acute stroke (ischemic or hemorrhagic) within prior 3 months * active major bleeding * severe thrombocytopenia (\<25,000/mm3) * increased risk of bleeding, as assessed by the investigator * acute or chronic renal insufficiency with creatinine clearance \< 30 ml/min calculated by the modified cockcroft and gault formula * weight \< 40 kg * known allergies to ingredients contained in enoxaparin, allergy to heparin products or history of heparin induced thrombocytopenia

- indication for full therapeutic-dose anticoagulation - acute venous thromboembolism (deep vein thrombosis or pulmonary embolism) within prior 3 months - acute cardiovascular event within prior 3 months - acute stroke (ischemic or hemorrhagic) within prior 3 months - active major bleeding - severe thrombocytopenia (<25,000/mm3) - increased risk of bleeding, as assessed by the investigator - acute or chronic renal insufficiency with creatinine clearance < 30 ml/min calculated by the modified cockcroft and gault formula - weight < 40 kg - known allergies to ingredients contained in enoxaparin, allergy to heparin products or history of heparin induced thrombocytopenia

- indication for full therapeutic-dose anticoagulation - acute venous thromboembolism (deep vein thrombosis or pulmonary embolism) within prior 3 months - acute cardiovascular event within prior 3 months - acute stroke (ischemic or hemorrhagic) within prior 3 months - active major bleeding - severe thrombocytopenia (<25,000/mm3) - increased risk of bleeding, as assessed by the investigator - acute or chronic renal insufficiency with creatinine clearance < 30 ml/min calculated by the modified cockcroft and gault formula - weight < 40 kg - known allergies to ingredients contained in enoxaparin, allergy to heparin products or history of heparin induced thrombocytopenia